Targeting mutant calreticulin in MPNs; focusing on bleeding risk in patients with cancer; revisiting diagnostic guidelines for familial HLH
This episode discusses targeting mutant calreticulin in myeloproliferative neoplasms, the bleeding risk in cancer patients as highlighted by the CAT-BLED study, and updated diagnostic guidelines for familial hemophagocytic lymphohistiocytosis.